Published in J Acquir Immune Defic Syndr on September 01, 1993
The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health (1996) 9.20
HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health (2001) 6.29
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (2012) 3.46
Drug abuse treatment as AIDS prevention. Public Health Rep (1998) 2.80
Take home maintenance medication in opiate dependence. Dtsch Arztebl Int (2013) 2.46
Needle exchange programs: an economic evaluation of a local experience. CMAJ (1997) 2.46
Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health (2006) 2.42
Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health (2006) 2.20
Black-white disparities in HIV/AIDS: the role of drug policy and the corrections system. J Health Care Poor Underserved (2005) 2.07
Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep (1998) 1.98
Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco. J Urban Health (2010) 1.97
Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep (1998) 1.92
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr (2014) 1.79
Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (2010) 1.79
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health (2000) 1.78
HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health (2000) 1.74
Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med (2005) 1.73
Why don't out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy (2008) 1.73
Facilitating treatment entry among out-of-treatment injection drug users. Public Health Rep (1998) 1.71
A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health (2014) 1.67
Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr (2010) 1.62
Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med (2006) 1.56
Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study. Clin Infect Dis (2014) 1.54
HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open (2012) 1.49
A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse (2009) 1.49
Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study. Lancet HIV (2015) 1.48
Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci (2007) 1.47
Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag (2009) 1.44
Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction (2015) 1.42
Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs (2009) 1.42
HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med (2014) 1.37
Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus (2012) 1.36
Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav (2013) 1.33
Clinical care of the HIV-infected drug user. Infect Dis Clin North Am (2007) 1.30
The pharmacological treatment of opioid addiction--a clinical perspective. Eur J Clin Pharmacol (2010) 1.30
Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations. Health Serv Res (2003) 1.29
The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood) (2011) 1.29
HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health (2010) 1.28
Methadone treatment for opiate addicts. BMJ (1996) 1.28
Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep (2010) 1.26
Group-based randomized trial of contingencies for health and abstinence in HIV patients. J Consult Clin Psychol (2010) 1.26
Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend (2011) 1.26
Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J Virol (2004) 1.23
HIV prevention among injection drug users: the need for integrated models. J Urban Health (2003) 1.22
Methadone maintenance treatment: a Canadian perspective. CMAJ (1997) 1.21
Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health (2007) 1.21
Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health (2009) 1.18
Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy (2010) 1.17
A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manag (2008) 1.14
Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse (2005) 1.10
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09
A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. PLoS One (2012) 1.09
The unrealized potential of addiction science in curbing the HIV epidemic. Curr HIV Res (2011) 1.08
Gender Differences Among In- and Out-of-Treatment Opioid-Addicted Individuals. Am J Drug Alcohol Abuse (2009) 1.08
A randomized trial of contingency management delivered in the context of group counseling. J Consult Clin Psychol (2011) 1.07
Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Econ (2008) 1.05
A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend (2012) 1.05
Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross-sectional survey. Harm Reduct J (2006) 1.04
HIV prevention with drug-using populations--current status and future prospects: introduction and overview. Public Health Rep (1998) 1.04
Better retention of Malaysian opiate dependents treated with high dose methadone in methadone maintenance therapy. Harm Reduct J (2010) 1.03
Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug Alcohol Depend (2013) 1.03
A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. Am J Public Health (1996) 1.02
Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions. J Subst Abuse Treat (2008) 1.01
A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China. Drug Alcohol Depend (2011) 1.00
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs (2014) 1.00
Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat (2011) 0.99
Reducing HIV-related risk behaviors among injection drug users in residential detoxification. AIDS Behav (2011) 0.99
Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (2008) 0.99
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs (2012) 0.99
The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Prev Med (2014) 0.97
Mitigating risky sexual behaviors among Russian narcology hospital patients: the PREVENT (Partnership to Reduce the Epidemic Via Engagement in Narcology Treatment) randomized controlled trial. Addiction (2008) 0.96
Methadone treatment at forty. Sci Pract Perspect (2005) 0.96
Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts. Drug Alcohol Depend (2010) 0.96
Scaling-up interim methadone maintenance: treatment for 1,000 heroin-addicted individuals. J Subst Abuse Treat (2009) 0.95
A randomized trial of oral naltrexone for treating opioid-dependent offenders. Am J Addict (2010) 0.94
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat (2007) 0.94
Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. J Subst Abuse Treat (2013) 0.92
HIV vaccine trials: will intravenous drug users enroll? Am J Public Health (1994) 0.92
A cluster randomized trial of an organizational linkage intervention for offenders with substance use disorders: study protocol. Health Justice (2013) 0.92
Redefining retention: recovery from the patient's perspective. J Psychoactive Drugs (2011) 0.91
Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. J Subst Abuse Treat (2012) 0.91
Impact of interim methadone maintenance on HIV risk behaviors. J Urban Health (2010) 0.91
Opioids and HIV/HCV infection. J Neuroimmune Pharmacol (2011) 0.91
Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med (2014) 0.91
Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. J Addict Med (2012) 0.90
Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-6. Sex Transm Infect (2000) 0.90
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev (2014) 0.89
Preliminary estimates of human immunodeficiency virus prevalence and incidence among cocaine abusers of Porto Alegre, Brazil. J Urban Health (2003) 0.87
Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility. J Public Health (Oxf) (2009) 0.87
Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend (2014) 0.86
An Empirical Ethics Agenda for Psychiatric Research Involving Prisoners. AJOB Prim Res (2011) 0.86
Projecting dynamic trends for HIV/AIDS in a highly endemic area of China: estimation models for Liangshan Prefecture, Sichuan Province. Curr HIV Res (2009) 0.86
Ignoring 'downstream infection' in the evaluation of harm reduction interventions for injection drug users. Eur J Epidemiol (2001) 0.86
Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies. Yale J Biol Med (2015) 0.86
Impact of a methadone maintenance therapy pilot in Vietnam and its role in a scaled-up response. Harm Reduct J (2015) 0.85
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment. J Subst Abuse Treat (2016) 0.85
Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users. J Appl Behav Anal (2014) 0.84
Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat (2013) 0.84
Implementation and Operational Research: Linkage to Care Among Methadone Clients Living With HIV in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr (2015) 0.83
The interplay between interpersonal dynamics, treatment barriers, and larger social forces: an exploratory study of drug-using couples in Hartford, CT. Subst Abuse Treat Prev Policy (2006) 0.83
An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis (1980) 14.25
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA (2000) 14.17
New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis (1985) 9.12
Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol (2000) 7.77
Limbic activation during cue-induced cocaine craving. Am J Psychiatry (1999) 6.66
Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis (1999) 5.99
The effects of psychosocial services in substance abuse treatment. JAMA (1993) 5.87
Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry (1992) 5.48
Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med (1998) 4.81
A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis (1992) 4.64
Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry (1999) 4.22
Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother (1986) 3.33
The economic costs of heroin addiction in the United States. Drug Alcohol Depend (2001) 2.90
Drug abuse treatment as AIDS prevention. Public Health Rep (1998) 2.80
Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Res Hum Retroviruses (1994) 2.62
Myths about the treatment of addiction. Lancet (1996) 2.58
Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. J Consult Clin Psychol (1994) 2.31
Conditioned responses to cocaine-related stimuli in cocaine abuse patients. Psychopharmacology (Berl) (1992) 2.29
Classical conditioning in drug-dependent humans. Ann N Y Acad Sci (1992) 2.28
Brain activity during simulated deception: an event-related functional magnetic resonance study. Neuroimage (2002) 2.26
Predicting response to alcohol and drug abuse treatments. Role of psychiatric severity. Arch Gen Psychiatry (1983) 2.25
Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr (1993) 2.23
beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis (1987) 2.17
A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat (1998) 2.15
Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med (1989) 2.11
Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry (1997) 2.07
Therapist success and its determinants. Arch Gen Psychiatry (1985) 2.00
Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat (1998) 1.98
Problem-service 'matching' in addiction treatment. A prospective study in 4 programs. Arch Gen Psychiatry (1997) 1.96
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) Arch Gen Psychiatry (1999) 1.94
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Lack of association between bacteriuria and symptoms in the elderly. Am J Med (1986) 1.85
Are supplementary services provided during methadone maintenance really cost-effective? Am J Psychiatry (1997) 1.81
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend (1999) 1.78
Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. Milbank Q (1996) 1.78
Breast cancer before age 45 and oral contraceptive use: new findings. Am J Epidemiol (1989) 1.76
Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. Br J Addict (1986) 1.69
Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat (2001) 1.68
Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer. Epidemiology (1990) 1.67
Effect of smoking cues and cigarette availability on craving and smoking behavior. Addict Behav (1996) 1.66
Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation. Arch Intern Med (1997) 1.64
Comparing levels of cocaine cue reactivity in male and female outpatients. Drug Alcohol Depend (1999) 1.64
Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis (2000) 1.62
Urinary tract infection: economic considerations. Med Clin North Am (1991) 1.62
Reliability and validity of the Addiction Severity Index with a homeless sample. J Subst Abuse Treat (1995) 1.60
Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addict Behav (1992) 1.57
Three decision-making tasks in cocaine-dependent patients: do they measure the same construct? Addiction (2001) 1.56
Classically conditioned responses in opioid and cocaine dependence: a role in relapse? NIDA Res Monogr (1988) 1.56
Endometrial cancer and age at last delivery: evidence for an association. Am J Epidemiol (1991) 1.55
Can you trust patient self-reports of drug use during treatment? Drug Alcohol Depend (1994) 1.53
Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry (1989) 1.53
Effect of random versus nonrandom assignment in a comparison of inpatient and day hospital rehabilitation for male alcoholics. J Consult Clin Psychol (1995) 1.52
Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) (1997) 1.49
Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry (1995) 1.49
Antisocial personality disorder in patients with substance abuse disorders: a problematic diagnosis? Am J Psychiatry (1990) 1.48
Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. Arch Gen Psychiatry (1983) 1.47
Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict (2001) 1.46
Psychotherapy for opiate addicts. Does it help? Arch Gen Psychiatry (1983) 1.42
Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav (2001) 1.41
Progress in the science of addiction. Am J Psychiatry (1997) 1.41
Immune response to influenza vaccination in a large healthy elderly population. Vaccine (1999) 1.41
Increased effectiveness of substance abuse treatment. A prospective study of patient-treatment "matching". J Nerv Ment Dis (1983) 1.40
Optimal treatment of urinary tract infections in elderly patients. Drugs Aging (1996) 1.39
One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend (1998) 1.39
Conditioned craving and arousal in cocaine addiction: a preliminary report. NIDA Res Monogr (1988) 1.38
Epidemiology of rubella. Am J Dis Child (1969) 1.38
Addiction severity index data from general membership and treatment samples of HMO members. One case of norming the ASI. J Subst Abuse Treat (2000) 1.37
Epidemiology of bacteriuria in an elderly ambulatory population. Am J Med (1986) 1.35
Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA (1970) 1.35
Interpreting the significance of drinking by alcohol-dependent liver transplant patients: fostering candor is the key to recovery. Liver Transpl (2000) 1.34
Multidimensional assessment of perceived treatment-entry pressures among substance abusers. Psychol Addict Behav (2001) 1.34
Crack cocaine abuse: an epidemic with many public health consequences. Annu Rev Public Health (1996) 1.34
Is the counselor an "active ingredient" in substance abuse rehabilitation? An examination of treatment success among four counselors. J Nerv Ment Dis (1988) 1.33
Repeat victims of violence: report of a large concurrent case-control study. Arch Surg (2000) 1.31
Sociopathy and psychotherapy outcome. Arch Gen Psychiatry (1985) 1.31